Effective of metastasis‐directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis
Head & Neck · 2023-10 · 45 (10) · 2571-2579
DOI: 10.1002/hed.27480 ↗Kurz gefasst
Fachartikel in der Zeitschrift Head & Neck, online erschienen am 09.08.2023. Verfasst von Guo-Ying Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Y…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
Our objective was to establish a prognostic model for patients with de novo metastatic nasopharyngeal carcinoma (NPC) who received chemotherapy followed by locoregional radiotherapy (LRRT) to identify candidates for metastasis‐directed therapy (MDT).
Methods
De novo metastatic NPC patients who received chemotherapy followed by LRRT were enrolled. Propensity score matching (PSM) method was used to compare overall survival (OS) for patients receiving LRRT alone and MDT plus LRRT. We developed a predictive model to predict survival and estimate the outcome of stratified therapy and identify suitable candidates for MDT.
Results
A total of 107 patients received MDT plus LRRT and 178 received LRRT alone were enrolled. PSM analysis identified 107 patients in each cohort and showed that MDT plus LRRT was associated with a significant survival benefit (HR: 0.640; 95% CI, 0.29–0.956; p = 0.027). Based on five independent prognostic factors, including metastases number, serum lactate dehydrogenase, liver metastasis, C‐reactive protein, and tumor response, a prognostic model was established. All patients were stratified according to the prognostic score obtained by the prognostic model. In the low‐risk group, MDT plus LRRT group revealed a significant improvement for OS compared with LRRT alone group (5‐year OS, 69.9% vs. 57.8%, p = 0.020). However, no significant difference was observed between MDT plus LRRT group and LRRT alone in the high‐risk group ( p = 0.75).
Conclusion
MDT plus LRRT was associated with improved OS in patients with de novo metastatic NPC, especially low‐risk patients identified with a newly developed prognostic model.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Medical Research Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Radiation Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Oncology, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou, China.
- Department of Nasopharyngeal Carcinoma, Sun Yat-Sen University Cancer Center, Guangzhou, Guangdong, China.
- State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-Sen University Cancer Center, Gua…
ORCID-Profile: Guo-Ying Liu
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Liu, G. Y., Li, Z., Chen, X. X., Xia, W. X., Yao, H. R., & Xiang, Y. Q. (2023). Effective of metastasis‐directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis. Head & Neck, 45(10), 2571-2579. https://doi.org/10.1002/hed.27480
Vancouver
Liu GY, Li Z, Chen XX, Xia WX, Yao HR, Xiang YQ. Effective of metastasis‐directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis. Head & Neck. 2023;45(10):2571-2579. doi:10.1002/hed.27480
BibTeX
@article{Liu2023,
author = {Liu, Guo-Ying and Li, Zhuo and Chen, Xiu-Xing and Xia, Wei-Xiong and Yao, He-Rui and Xiang, Yan-Qun},
title = {Effective of metastasis‐directed therapy for de novo metastatic nasopharyngeal carcinoma: A propensity score matched analysis},
journal = {Head & Neck},
year = {2023},
volume = {45},
number = {10},
pages = {2571--2579},
doi = {10.1002/hed.27480}
}
EUVIMED